Janney Montgomery Scott LLC Sells 1,590 Shares of Masimo Corporation (NASDAQ:MASI)

Janney Montgomery Scott LLC lowered its holdings in Masimo Corporation (NASDAQ:MASI - Free Report) by 47.4% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,762 shares of the medical equipment provider's stock after selling 1,590 shares during the period. Janney Montgomery Scott LLC's holdings in Masimo were worth $294,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. apricus wealth LLC raised its position in shares of Masimo by 12.2% during the 1st quarter. apricus wealth LLC now owns 1,462 shares of the medical equipment provider's stock worth $244,000 after purchasing an additional 159 shares during the period. GAMMA Investing LLC raised its position in shares of Masimo by 58.4% during the 1st quarter. GAMMA Investing LLC now owns 738 shares of the medical equipment provider's stock worth $123,000 after purchasing an additional 272 shares during the period. Farther Finance Advisors LLC raised its position in shares of Masimo by 128.9% during the 1st quarter. Farther Finance Advisors LLC now owns 206 shares of the medical equipment provider's stock worth $35,000 after purchasing an additional 116 shares during the period. UMB Bank n.a. raised its position in shares of Masimo by 134.0% during the 1st quarter. UMB Bank n.a. now owns 447 shares of the medical equipment provider's stock worth $74,000 after purchasing an additional 256 shares during the period. Finally, RFG Advisory LLC raised its position in shares of Masimo by 73.6% during the 1st quarter. RFG Advisory LLC now owns 6,780 shares of the medical equipment provider's stock worth $1,130,000 after purchasing an additional 2,875 shares during the period. Institutional investors and hedge funds own 85.96% of the company's stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on MASI. Raymond James Financial decreased their price objective on Masimo from $204.00 to $185.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. Wall Street Zen lowered Masimo from a "buy" rating to a "hold" rating in a research note on Friday, May 30th. Needham & Company LLC reaffirmed a "hold" rating on shares of Masimo in a research note on Thursday, April 10th. BTIG Research set a $193.00 price target on Masimo and gave the company a "buy" rating in a research note on Wednesday, May 7th. Finally, Wells Fargo & Company decreased their price target on Masimo from $205.00 to $190.00 and set an "overweight" rating for the company in a research note on Wednesday, May 7th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, Masimo presently has a consensus rating of "Moderate Buy" and a consensus target price of $191.60.

Masimo Price Performance

NASDAQ MASI traded up $3.06 during trading on Wednesday, reaching $165.41. 389,091 shares of the company traded hands, compared to its average volume of 640,502. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.62 and a current ratio of 2.17. The stock's 50 day moving average price is $161.93 and its two-hundred day moving average price is $166.35. The company has a market cap of $8.97 billion, a price-to-earnings ratio of -18.04 and a beta of 1.19. Masimo Corporation has a 1-year low of $101.61 and a 1-year high of $194.88.

Masimo (NASDAQ:MASI - Get Free Report) last posted its earnings results on Tuesday, May 6th. The medical equipment provider reported $1.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.24 by $0.12. Masimo had a negative net margin of 25.06% and a positive return on equity of 22.56%. The company had revenue of $372.00 million during the quarter, compared to analysts' expectations of $367.79 million. During the same quarter in the previous year, the company posted $0.77 earnings per share. Masimo's quarterly revenue was down 24.5% compared to the same quarter last year. As a group, analysts anticipate that Masimo Corporation will post 4.1 EPS for the current year.

Insider Activity at Masimo

In other news, COO Bilal Muhsin sold 10,000 shares of the business's stock in a transaction on Monday, May 12th. The shares were sold at an average price of $163.28, for a total value of $1,632,800.00. Following the completion of the transaction, the chief operating officer owned 24,172 shares of the company's stock, valued at $3,946,804.16. The trade was a 29.26% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 9.70% of the company's stock.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.